Management Quality -- 8/10
RMD management earns a strong 8/10 based on a perfect promise-keeping record (9 of 12 promises fully
delivered or exceeded, zero misses, 3 in progress and on track), gross margin guidance raised twice
(from 59-60% to 61-63%, then narrowed to 62-63%), masterful GLP-1 narrative management that turned
an existential fear into a validated tailwind with 1.95M-patient real-world evidence, and disciplined
capital allocation with systematic buyback ramp and sensible tuck-in M&A. Withheld from 9+ due to
key-man concentration on Farrell, RCS reacceleration still being a promise rather than a delivered
result, and a minor SG&A discipline crack in Q2 FY2026.
Weight: 20%
CEO
Mick Farrell (since 2013)
Chairman and CEO | Son of founder Peter Farrell | 25+ years at RMD | Incoming AdvaMed Chairman
Promise Delivery
9 MET/BEAT, 0 MISS, 3 IN PROGRESS
12 promises tracked across 6 quarters; zero misses identified
Non-GAAP Gross Margin
62.3% (Q2 FY2026)
Expanded 290 bps over 6 quarters (58.5% to 61.4% in FY2025) | Guidance raised to 62-63%
LTM Free Cash Flow
$1.66B (+52% over 6Q)
Up from $1.09B | Net cash position of $753M | $1.5B revolver undrawn
Leadership team
Mick Farrell -- Chairman and CEO (since 2013, 25+ years at RMD)
Son of founder Peter Farrell. Deep domain expertise in sleep health and respiratory medicine.
Incoming Chairman of AdvaMed (industry group), giving direct regulatory advocacy channel.
Dominates every earnings call -- prepared remarks and nearly all Q&A answers. Deeply knowledgeable
and engaged, but this creates key-man concentration risk. Masterfully turned the GLP-1 narrative
from existential threat to validated tailwind using a 1.95M-patient real-world evidence program.
Communicates strategy with high conviction and specificity through the ResMed 2030 framework.
Brett Sandercock -- CFO (10+ years)
Conservative, precise communicator based in Sydney. Ran operations for 6+ months during supply
chain leadership transition, demonstrating versatility beyond the finance function. Handles
financial details on calls but defers to Farrell on all strategic questions. Consistently
delivers clean guidance with narrow ranges that are met or beaten. Provides transparent
reconciliation between GAAP and non-GAAP metrics with minimal adjustments.
Rob Douglas -- President and COO
Barely mentioned across 6 transcripts -- Farrell has effectively consolidated the public-facing
leadership role. This is not necessarily negative given Farrell is deeply knowledgeable, but it
does mean investor visibility into the operational bench is limited. If Farrell were to depart,
the investor-facing void would be significant.
Shane Azzi -- Chief Supply Chain Officer (~1 year)
Credited with transforming supply chain from "arts to science" approach. Driving a multi-year
pipeline of gross margin initiatives described as sustainable. Freight costs back to pre-COVID
levels. The AS10-to-AS11 transition under his watch is delivering structural margin gains.
Calabasas manufacturing expansion (doubling US capacity) opened June 2025 on schedule.
Promise vs. delivery tracker (12 promises)
| When Promised | Promise | Evidence | Grade |
|---|---|---|---|
| Q1 FY2025 | Gross margin 59-60% for FY2025 | Actuals: 59.2%, 59.2%, 59.9%, 61.4%. FY2025 avg ~59.9%. Exceeded high end in Q4. | BEAT |
| Q4 FY2025 | Gross margin 61-63% for FY2026 | Q1 FY2026: 62.0%, Q2 FY2026: 62.3%. Tracking solidly. Raised to 62-63% in Q2. | ON TRACK -- RAISED |
| Q1 FY2025 | SG&A 18-20% of revenue | All quarters within range: 19.5%, 18.8%, 19.0%, 19.7%, 19.4%, 19.6%. | MET |
| Q1 FY2025 | R&D 6-7% of revenue | All quarters within range: 6.5%, 6.3%, 6.5%, 6.4%, 6.5%, 6.4%. | MET |
| Investor Day Sept 2024 | High-single-digit revenue; better profit growth; better EPS growth | Revenue +8-11% each quarter. Non-GAAP EPS +11-34%. Profit growth consistently faster. | BEAT |
| Q1 FY2025 | AirSense 11 off allocation by end CY2024 | Vast majority of US sales are AS11 by Q2 FY2025. No further allocation complaints. | MET |
| Q1 FY2025 | AirTouch N30i fabric mask launch (next week) | Launched on schedule. Positive RT/physician/patient feedback by Q2 FY2025. Expanded to F30i variants. | MET |
| Q1 FY2026 | RCS reacceleration to high-single-digit by FY2027 | RCS grew +5% CC in Q1-Q2 FY2026. Portfolio management underway. Still mid-single-digit. | IN PROGRESS |
| Multiple calls | Share buyback: ~$75M/qtr FY2025, ~$150M/qtr FY2026, >$600M total FY2026 | FY2025: $300M (ramping as promised). FY2026 H1: $325M ($150M + $175M). On track for >$600M. Dividend raised 13%. | BEAT -- ACCELERATING |
| Q1 FY2025 onward | GLP-1s are a tailwind, not a headwind | 1.95M patients studied. Start rates +10-11% higher, 3-yr resupply +6.2% higher. Thesis fully validated. | BEAT -- STRONG EVIDENCE |
| Q3 FY2025 | Calabasas manufacturing expansion (doubling US capacity) by June 2025 | On track per Q3 FY2025. Confirmed approaching official opening in Q4 FY2025. | MET |
| Q1 FY2026 | Indianapolis distribution center operational in 2027 | Lease signed, construction started per Q2 FY2026. On track. | IN PROGRESS -- ON TRACK |
9 of 12 promises fully delivered or exceeded. 3 in progress and on track. Zero misses identified.
Management demonstrated a consistent pattern of under-promising and over-delivering, with gross margin
guidance raised twice through the review period.
Source: Daloopa, earnings call transcripts Q1 FY2025 - Q2 FY2026.
Daloopa financial verification (6 quarters)
| Metric | Q1 CY24 (FQ3) | Q2 CY24 (FQ4) | Q3 CY24 (FQ1) | Q4 CY24 (FQ2) | Q1 CY25 (FQ3) | Q2 CY25 (FQ4) |
|---|---|---|---|---|---|---|
| Revenue ($M) | $1,197 | $1,223 | $1,225 | $1,282 | $1,292 | $1,348 |
| Non-GAAP Gross Margin | 58.5% | 59.1% | 59.2% | 59.2% | 59.9% | 61.4% |
| GAAP Diluted EPS | $2.04 | $1.98 | $2.11 | $2.34 | $2.48 | $2.58 |
| Non-GAAP Diluted EPS | $2.13 | $2.08 | $2.20 | $2.43 | $2.37 | $2.55 |
| Free Cash Flow LTM ($M) | $1,090 | $1,302 | $1,353 | $1,392 | $1,569 | $1,662 |
Revenue up ~13% over 6 quarters. Non-GAAP gross margin expanded 290 bps (58.5% to 61.4%).
LTM FCF up 52% ($1.09B to $1.66B). Non-GAAP EPS up 20% ($2.13 to $2.55).
Consistent, broad-based improvement across all metrics.
Qualitative assessment
Exceptional Execution Consistency
Every financial guidance range given across 6 quarters was met or beaten. Gross margin guidance
was raised twice (from 59-60% to 61-63%, then narrowed to 62-63%). This is a hallmark of a
management team that under-promises and over-delivers. The ResMed 2030 strategy (3 pillars:
core sleep/breathing, adjacencies, digital health) is consistently articulated with high
conviction and specificity, not vague platitudes.
GLP-1 Narrative Management Was Masterful
In 2023-2024, GLP-1 fears hammered the stock. Rather than being defensive, Farrell built a
massive real-world evidence program (now 1.95M patients) and turned the narrative from
"existential threat" to "net tailwind" with hard data. The 3-year resupply data showing 6.2%
higher adherence is the capstone. Start rates are +10-11% higher for GLP-1 users. This was
proactive, data-driven, and highly effective -- textbook management of an exogenous risk.
Disciplined Capital Allocation
Systematic ramp from $50M/qtr buybacks to $175M/qtr, 13% dividend increase, tuck-in M&A
(VirtuOx, Ectosense, Somnoware) at modest valuations ($140M for VirtuOx at ~3x revenue).
No empire-building. Clear criteria for M&A: strategic fit, financial returns, cultural
alignment. Net cash position of $753M with $1.5B revolver undrawn. Debt at attractive fixed rates.
Innovation Cadence and Supply Chain Transformation
Fabric mask technology (AirTouch N30i, F30i Clear, F30i Comfort) is genuinely differentiated.
NightOwl diagnostic, vPAP TX titration platform, AI-based Comfort Match (first FDA-cleared
AI-enabled medical device), Dawn generative AI assistant -- all launched in the review period.
R&D spend consistently at 6-7% of revenue. Supply chain transformed under Shane Azzi with
freight costs back to pre-COVID levels and a multi-year margin improvement pipeline.
Red flags check
| Flag | Status | Detail |
|---|---|---|
| Guidance misses / lowered guidance | NO | All guidance met or raised across 6 quarters. |
| Aggressive revenue recognition | NO | Revenue is product shipment based; SaaS is subscription. No unusual items. |
| Non-GAAP divergence from GAAP | MINIMAL | Adjustments limited to amortization of acquired intangibles, restructuring ($16M+$6M), one-time tax items. Clean reconciliation. |
| Executive turnover | LOW | Bobby Ghoshal (RCS CCO) departed Q4 FY2025 -- positioned as planned. New IR officer (Salli Schwartz) joined Q3 FY2025. |
| Related-party transactions | NO | Farrell is son of founder, but no flagged related-party issues. |
| Acquisition integration issues | NO | VirtuOx, Ectosense, Somnoware all small tuck-ins; neutral to EPS at worst. No goodwill impairment risk. |
| Balance sheet concerns | NO | Net cash position of $753M (Q2 FY2026). $1.5B revolver undrawn. Debt at attractive fixed rates. |
| Accounting changes | NO | No unusual accounting policy changes noted. |
| Customer concentration | NO | Broad base of HME providers, hospitals, direct consumers across 140 countries. |
Red flags detected: 0 of 9. Clean across all categories. Insider selling not assessed (not available in transcript data).
Strengths and concerns
Strengths
1. Perfect promise-tracking record. 9 of 12 promises fully delivered or exceeded
across 6 quarters. Zero misses. Multiple beats. Gross margin guidance raised twice. This is a
management team that consistently under-promises and over-delivers.
2. Strategic foresight on GLP-1s. Turned the GLP-1 narrative from existential headwind to validated tailwind with hard evidence (1.95M patient study). Start rates +10-11% higher, 3-year resupply +6.2% higher for GLP-1 users. Proactive, data-driven, and highly effective.
3. Disciplined capital allocation. Systematic buyback ramp from $50M/qtr to $175M/qtr. 13% dividend increase. Sensible tuck-in M&A at modest valuations. No empire building. Net cash balance sheet with $753M cash and $1.5B undrawn revolver.
4. Sustained gross margin expansion. 290 bps expansion over the review period (58.5% to 61.4%) with a clear pipeline for continued improvement under Shane Azzi. Science-based supply chain approach described as multi-year and sustainable.
5. Strong innovation cadence. Fabric masks, NightOwl diagnostic, AI-based Comfort Match (first FDA-cleared AI-enabled medical device), Dawn generative AI assistant. R&D consistently at 6-7% of revenue. Tariff and regulatory preparedness (AdvaMed chairmanship, CPAP excluded from competitive bidding for first time in 15 years).
2. Strategic foresight on GLP-1s. Turned the GLP-1 narrative from existential headwind to validated tailwind with hard evidence (1.95M patient study). Start rates +10-11% higher, 3-year resupply +6.2% higher for GLP-1 users. Proactive, data-driven, and highly effective.
3. Disciplined capital allocation. Systematic buyback ramp from $50M/qtr to $175M/qtr. 13% dividend increase. Sensible tuck-in M&A at modest valuations. No empire building. Net cash balance sheet with $753M cash and $1.5B undrawn revolver.
4. Sustained gross margin expansion. 290 bps expansion over the review period (58.5% to 61.4%) with a clear pipeline for continued improvement under Shane Azzi. Science-based supply chain approach described as multi-year and sustainable.
5. Strong innovation cadence. Fabric masks, NightOwl diagnostic, AI-based Comfort Match (first FDA-cleared AI-enabled medical device), Dawn generative AI assistant. R&D consistently at 6-7% of revenue. Tariff and regulatory preparedness (AdvaMed chairmanship, CPAP excluded from competitive bidding for first time in 15 years).
Concerns
1. Key-man risk on Farrell. Mick Farrell dominates every earnings call -- prepared
remarks and nearly all Q&A answers. Rob Douglas is essentially invisible in transcripts.
If Farrell departed, the investor-facing void would be significant. Brett Sandercock handles
financials but defers on all strategic questions.
2. RCS growth deceleration. Software segment slowed from 12% (Q1 FY25) to 5% CC (Q1-Q2 FY26). Portfolio management (cutting lower-margin services) is sensible but the reacceleration to high-single-digit is still a promise, not a delivered result. The departure of Bobby Ghoshal (CCO of RCS) in Q4 FY2025 adds execution risk.
3. SG&A creep in Q2 FY2026. SG&A grew 12% CC vs. 9% CC revenue growth. Management attributes it to VirtuOx integration and marketing investments. Not alarming yet, but divergence from prior operating leverage trend worth monitoring.
4. Verbal density / promotional tone. Farrell prepared remarks are extremely lengthy and promotional. While the substance is strong, the style can make it harder to identify genuinely new information vs. repetition of prior talking points. Minor stylistic concern.
2. RCS growth deceleration. Software segment slowed from 12% (Q1 FY25) to 5% CC (Q1-Q2 FY26). Portfolio management (cutting lower-margin services) is sensible but the reacceleration to high-single-digit is still a promise, not a delivered result. The departure of Bobby Ghoshal (CCO of RCS) in Q4 FY2025 adds execution risk.
3. SG&A creep in Q2 FY2026. SG&A grew 12% CC vs. 9% CC revenue growth. Management attributes it to VirtuOx integration and marketing investments. Not alarming yet, but divergence from prior operating leverage trend worth monitoring.
4. Verbal density / promotional tone. Farrell prepared remarks are extremely lengthy and promotional. While the substance is strong, the style can make it harder to identify genuinely new information vs. repetition of prior talking points. Minor stylistic concern.
Score rationale
8/10. ResMed management earns a strong 8 through: (a) a perfect promise-tracking
record across 6 quarters with 9 of 12 delivered or exceeded and zero misses, (b) masterful GLP-1
narrative management that turned an existential fear into a validated tailwind with 1.95M-patient
evidence, (c) disciplined capital allocation with increasing shareholder returns and sensible
tuck-in M&A, (d) sustained gross margin expansion of 290 bps with a clear pipeline for
continued improvement, and (e) strong innovation cadence in both hardware and software/AI.
Why not 9+: The 9-10 range is reserved for management teams with both flawless execution AND no open questions. Key-man concentration on Farrell with limited bench depth visible externally is a structural risk. RCS reacceleration to high-single-digit growth is still a promise, not yet a delivered result. SG&A discipline showed a crack in Q2 FY2026 (12% growth vs. 9% revenue growth). This is a high-quality, owner-operator-style management team, but these open items prevent the highest tier.
What would move this to 9+: RCS reaccelerating to high-single-digit growth as promised. Visible bench depth -- Douglas or other executives taking more prominent roles on calls. SG&A returning to leverage trend (growing slower than revenue). Continued gross margin expansion into the 62-63% range for the full year. The stock drawdown of 24% from 52-week highs does not appear to reflect management quality deterioration.
Why not 9+: The 9-10 range is reserved for management teams with both flawless execution AND no open questions. Key-man concentration on Farrell with limited bench depth visible externally is a structural risk. RCS reacceleration to high-single-digit growth is still a promise, not yet a delivered result. SG&A discipline showed a crack in Q2 FY2026 (12% growth vs. 9% revenue growth). This is a high-quality, owner-operator-style management team, but these open items prevent the highest tier.
What would move this to 9+: RCS reaccelerating to high-single-digit growth as promised. Visible bench depth -- Douglas or other executives taking more prominent roles on calls. SG&A returning to leverage trend (growing slower than revenue). Continued gross margin expansion into the 62-63% range for the full year. The stock drawdown of 24% from 52-week highs does not appear to reflect management quality deterioration.
Data sourced from Daloopa and earnings call transcripts Q1 FY2025 - Q2 FY2026.